The Leslie Dan Faculty of Pharmacy from University of Toronto, Canada, awarded six Alumni Awards (https://www.pharmacy.utoronto.ca/news-announcements/exceptional-alumni-recognized-through-second-annual-alumni-awards) in different categories recognizing the remarkable achievements of alumni in pharmacy practice and pharmaceutical sciences.
We proudly present the new article by Silvia Colucci, Sandro Altamura and Martina Muckenthaler from our FerrOs Research Group on "Liver Sinusoidal Endothelial Cells Suppress Bone Morphogenetic Protein 2 Production in Response to TGFβ Pathway Activation" that was just published in Hepatology (https://pubmed.ncbi.nlm.nih.gov/33982327/).
Our second FerrOs Webinar took place on September 28th. The FerrOs members were very keen on listening to the excellent talk of Delphine Meynard, who presented her newest work on the role of matripase-2 as a novel therapeutic target in diseases with ineffective hematopoiesis. Besides the stimulating talk, it was great to see each other again and get to know new members of the FerrOs consortium.
Meetings during pandemic times – on June 4th we met online at our 1st FerrOs Retreat. Although we were not able to meet face-to-face, we were all very happy to “see” each other online and listen to the eight FerrOs projects so all new members could see what is planned and to discuss how we can interact during the next four years.
Our newly funded Research Unit “FerrOs” officially started in March 2021 and will study the effects of iron metabolism on bone and liver health.
Iron deﬁciency and iron overload are both associated with bone loss and an increased risk of fracture, which markedly limit mobility and autonomy of aﬀected individuals. Thus, iron levels must be balanced to maintain health in general, and in particular bone strength. Therefore, the main aim of our DFG-funded FerrOs consortium (FOR5146) is to decipher the underlying mechanisms of iron regulation and its interactions with bone.